Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies
Circassia also advances Phase III Plans for cat Allergy T-Cell Vaccine
Circassia Ltd announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines. In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of phase II testing with its ragweed allergy treatment and progressed phase III development plans for its cat allergy therapy. This progress builds on four earlier successful phase II studies of Circassia's ToleroMune® technology, which scientifically validated the use of novel T-cell vaccines in treating allergies and identified the optimal dosing approach.
"These recent clinical advances demonstrate Circassia's commitment to bringing its unique T-cell allergy vaccines to market as rapidly as possible," said Steve Harris, Circassia's CEO. "Since the founding of Circassia just four years ago, our ToleroMune® technology has successfully completed multiple phase II studies, and we now have four therapies in mid-stage development, targeting some of the most common allergies in the world. As a result, our growing clinical database demonstrates the potential of our novel T-cell vaccines to provide allergy sufferers with short, simple and convenient treatment, whilst minimising the risk of severe and sometimes life-threatening side effects associated with many existing immunotherapies."
Other news from the department research and development
